Unknown

Dataset Information

0

Gene Correction of LGMD2A Patient-Specific iPSCs for the Development of Targeted Autologous Cell Therapy.


ABSTRACT: Limb girdle muscular dystrophy type 2A (LGMD2A), caused by mutations in the Calpain 3 (CAPN3) gene, is an incurable autosomal recessive disorder that results in muscle wasting and loss of ambulation. To test the feasibility of an autologous induced pluripotent stem cell (iPSC)-based therapy for LGMD2A, here we applied CRISPR-Cas9-mediated genome editing to iPSCs from three LGMD2A patients to enable correction of mutations in the CAPN3 gene. Using a gene knockin approach, we genome edited iPSCs carrying three different CAPN3 mutations, and we demonstrated the rescue of CAPN3 protein in myotube derivatives in vitro. Transplantation of gene-corrected LGMD2A myogenic progenitors in a novel mouse model combining immunodeficiency and a lack of CAPN3 resulted in muscle engraftment and rescue of the CAPN3 mRNA. Thus, we provide here proof of concept for the integration of genome editing and iPSC technologies to develop a novel autologous cell therapy for LGMD2A.

SUBMITTER: Selvaraj S 

PROVIDER: S-EPMC6904833 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Gene Correction of LGMD2A Patient-Specific iPSCs for the Development of Targeted Autologous Cell Therapy.

Selvaraj Sridhar S   Dhoke Neha R NR   Kiley James J   Mateos-Aierdi Alba Judith AJ   Tungtur Sudheer S   Mondragon-Gonzalez Ricardo R   Killeen Grace G   Oliveira Vanessa K P VKP   López de Munain Adolfo A   Perlingeiro Rita C R RCR  

Molecular therapy : the journal of the American Society of Gene Therapy 20190828 12


Limb girdle muscular dystrophy type 2A (LGMD2A), caused by mutations in the Calpain 3 (CAPN3) gene, is an incurable autosomal recessive disorder that results in muscle wasting and loss of ambulation. To test the feasibility of an autologous induced pluripotent stem cell (iPSC)-based therapy for LGMD2A, here we applied CRISPR-Cas9-mediated genome editing to iPSCs from three LGMD2A patients to enable correction of mutations in the CAPN3 gene. Using a gene knockin approach, we genome edited iPSCs c  ...[more]

Similar Datasets

| S-EPMC3480729 | biostudies-literature
2012-03-30 | GSE28607 | GEO
| S-EPMC8403427 | biostudies-literature
| S-EPMC5413600 | biostudies-literature
| S-EPMC6523438 | biostudies-literature
| S-EPMC10471463 | biostudies-literature
| S-EPMC4705535 | biostudies-literature
| S-EPMC4559351 | biostudies-literature
| S-EPMC9409156 | biostudies-literature
| S-EPMC5363452 | biostudies-literature